MEDIWELCOME Reports Interim Results: Swings to Profit with 17.9 Million Yuan Attributable to Owners

MEDIWELCOME (02159) has released its interim results for 2026, reporting a revenue of approximately 231 million yuan, representing a year-on-year increase of about 81.7%. Gross profit stood at roughly 69.7 million yuan, up approximately 219.7% from the prior period. The company recorded a profit attributable to owners of 17.903 million yuan, reversing a loss from the same period last year. Earnings per share were 7.85 fen.

During the reporting period, the group's core business segments maintained stable operations, with a continued focus on using technological innovation to empower business scenarios. Leveraging its deep expertise and vast professional resources in the healthcare sector, the group steadily enhanced the service depth and application coverage of its digital-intelligent products. While consolidating its traditional strengths, the group actively expanded its innovative business landscape and comprehensively optimized operational efficiency.

Overall, the group's management remained efficient and orderly, with the business structure continuing to shift toward higher-value-added areas. This sets a solid foundation for sustainable growth throughout the year and long-term value restructuring.

On the strategic and technological innovation front, the group deepened its research and scenario-based application of the "AI vertical model + blockchain" underlying architecture, aiming to address industry pain points related to professional depth and data compliance encountered by general large models. During the reporting period, the group's core technology platform, the "Giraffe Digital-Intelligent Integration Platform," completed a phased upgrade and iteration, further integrating AI agents, medical disease-specific knowledge bases, and clinical workflows. In terms of disease-specific model development, the group, while strengthening its advantages in fields like cerebrovascular disease, actively expanded into high-incidence areas such as cardiovascular and respiratory diseases, continuously enriching its structured specialist language corpus.